Open Letter to the Members of the Pharmabiotic Research Institute (PRI), Fall 2020 This has been a truly exceptional and distressing year for many in the world – both professionally and personally. We the Staff at the PRI on behalf of the President Bruno Pot and the Board of Directors would like to extend our […]
Live Biotherapeutics developers will need to incorporate gold-standard pharmaceutical development techniques and approaches in order to reach market and patients in need The Pharmabiotic Research Institute (PRI), Europe’s only regulatory expertise centre for the development of microbiome-based drug products, has announced the publication of a review titled “Live biotherapeutic products: the importance of a defined […]
Live Biotherapeutic Products – a new regulatory approach for the safety assessment of a specific category of biological medicinal products NARBONNE, France – An article has been published in Frontiers in Medicine: Regulatory Science section, which proposes a new set of recommendations for addressing the various regulatory and technical challenges when assessing the safety of […]
The following is an open letter to the Members of the Pharmabiotic Research Institute (PRI). Dear Members, partners and friends of the Pharmabiotic Research Institute (PRI), As the year 2019 ends, we find ourselves reflecting on the last 12 months and what has been learned, discussed, accomplished, and what work still lies ahead… In 2020 […]
Written by Kristina Campbell – This article originally appeared in the online publication The Microbiome Times Many individuals living with chronic disease—whether it’s asthma, allergies, atopic dermatitis, type 2 diabetes, or another condition—readily confirm their therapeutic options leave a lot to be desired. Even if an existing drug product deals adequately with their symptoms, it often […]
